OASL: 2'-5'-Oligoadenylate Synthetase Like
Interferon-induced antiviral and tumor suppressor gene
Gene Information Card
| Symbol | OASL |
|---|---|
| Full Name | 2'-5'-Oligoadenylate Synthetase Like |
| Gene Type | Protein coding |
| Chromosomal Location | 12q24.31 |
| NCBI Gene ID | 8638 ncbi.nlm.nih.gov/gene/8638 |
| Ensembl ID | ENSG00000135114 |
| UniProt ID | Q15646 |
| OMIM ID | 603281 |
| HGNC ID | 8090 |
| Aliases | TRIP14, OASL1, p59 OASL, OASLd |
Description
OASL (2'-5'-Oligoadenylate Synthetase Like) is an interferon-inducible gene that encodes a protein belonging to the 2'-5'-oligoadenylate synthetase family. Unlike classical OAS enzymes, OASL lacks canonical 2'-5'-oligoadenylate synthetase activity but plays a critical role in antiviral innate immunity by enhancing RIG-I signaling and modulating interferon responses. It is also implicated in tumor suppression and autoimmune regulation.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Viral infections (e.g., influenza, hepatitis C) | OASL enhances RIG-I-mediated interferon induction, restricting viral replication | PMID: 21957124 |
| Systemic lupus erythematosus (SLE) | OASL overexpression linked to interferon signature and autoimmunity | PMID: 25605271 |
| Colorectal cancer | OASL acts as a tumor suppressor via modulation of interferon signaling and apoptosis | PMID: 31570879 |
| Breast cancer | OASL expression correlates with prognosis and immune infiltration | PMID: 32697978 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lung | 12.5 | Medium |
| Spleen | 18.3 | Medium |
| Liver | 8.9 | Low |
| Small intestine | 15.1 | Medium |
| Whole blood | 5.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 22.4 | High expression |
| A549 | 16.8 | Medium expression |
| HepG2 | 10.3 | Low expression |
| MCF7 | 14.7 | Medium expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1045C>T (p.Arg349Trp) | Missense | 0.001% (gnomAD) | Unknown functional impact |
| c.1282G>A (p.Glu428Lys) | Missense | 0.002% (gnomAD) | Potential loss of interferon induction |
| c.1546_1547insA | Frameshift | <0.001% | Predicted loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense variants that truncate the protein likely impair OASL's ability to enhance RIG-I signaling.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
Not established; potential dominant-negative effects of missense variants remain uncharacterized.
View complete mutation data：
Gene Ontology (GO)
Pathways
• RIG-I/MDA5 mediated induction of interferon-alpha/beta (Reactome: R-HSA-168928)
• Interferon alpha/beta signaling (Reactome: R-HSA-909733)
• Antiviral mechanism by IFN-stimulated genes (Reactome: R-HSA-1169410)
Protein Summary
The OASL protein (59 kDa) contains a single N-terminal nucleotidyltransferase domain and two C-terminal ubiquitin-like domains. It lacks the canonical DFD motif required for 2'-5'-oligoadenylate synthesis but retains RNA binding ability. OASL amplifies RIG-I signaling by mimicking polyubiquitin chains, promoting IRF3 and NF-κB activation. It is strongly induced by type I interferons and plays a dual role in antiviral defense and cancer modulation.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| OASL Knockout HEK293 Cell Line | EDJ-KQ6317 | Human | 8638 | Details Get a Quote |
| OASL Knockout HeLa Cell Line | EDJ-KQ28929 | Human | 8638 | Details Get a Quote |
| OASL Knockout A-549 Cell Line | EDJ-KQ30239 | Human | 8638 | Details Get a Quote |
| OASL Knockout HCT 116 Cell Line | EDJ-KQ30240 | Human | 8638 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
